mo:re
Germany
- Hamburg
- 01/04/2025
- Seed
- $2,485,277
Your new teammate in the lab! Our lab platform takes over tedious and error-prone manual tasks in 3D cell culture, aiming to replace animal studies. A standardised repository of protocols lets you set up new experiments within minutes. Our AI-based quality control provides real-time transparency on the state of your cell culture, allowing you to worry less and make well-informed decisions.
- Industry Biotechnology Research
- Website https://more.science/
- LinkedIn https://www.linkedin.com/company/more-lifesciences/
Related People
Lukas GaatsFounder
Germany -
Hamburg, Hamburg
Co-founder & CEO of mo:re, a biotechnology start-up building the new gold standard for organoid-based drug development by offering a lab platform that industrialises cell culture workflows.
Our platform of a lab robot and software replaces animal studies with AI-assisted cultivation of disease models on which new compounds can be tested in a standardised and high-throughput fashion. This enables scaling up experiments without compromising traceability and quality to bridge the gap between PoC and industry experiments.
Visit mo:re https://more.science
Vesence | $9,000,000 | (Oct 30, 2025)
Sparrow BioAcoustics | $10,000,000 | (Oct 30, 2025)
Reflectiz | $22,000,000 | (Oct 30, 2025)
Mem0 | $24,000,000 | (Oct 30, 2025)
Valthos | $30,000,000 | (Oct 30, 2025)
Mondra | $13,206,500 | (Oct 30, 2025)
hoop.dev | Undisclosed Amount | (Oct 30, 2025)
IORGANBIO | $2,000,000 | (Oct 30, 2025)
FrontlineIQ | $3,300,000 | (Oct 30, 2025)
Homecourt | $8,000,000 | (Oct 30, 2025)
VentureMed Inc. | $28,000,000 | (Oct 30, 2025)
Recess | $30,000,000 | (Oct 30, 2025)